MedWatch

Oncology Venture wins CE marking for diagnostic tool

Scandinavian biotech Oncology Venture has won regulatory approval in the EU for a diagnostic tool used to predict which patients might benefit from its lead candidate.

Foto: Colourbox

Denmark-base, Sweden-listed biotech Oncology Venture, a spin off from Medical Prognosis Institute (MPI), has won CE marking of its Drug Response Predictor (DRP) – a companion tool for its lead drug candidate LiPLaCis against breast cancer.

This is according to a press release from the company.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier